GSK To Supply Combivir For NIH-Funded AIDS Trial Following Rep. Waxman Letter
This article was originally published in The Pink Sheet Daily
GSK initially offered the HIV therapy for free but withdrew from the clinical trial in Africa after investigators revised one of three study arms, setting up a comparative effectiveness trial, Waxman says. GSK will now offer the drug at a "nonprofit," "developing country" price of 65¢ per day.
You may also be interested in...
NIH cannot grant Norvir patent licenses under the Bayh/Dole Act until Abbott has exhausted its appeals process, and follow-on products would have to gain standard FDA approval, the agency says. NIH expects to make a decision on whether to apply its "march-in" authority for the HIV product as soon as possible. The precedent established could have an immediate effect; NIH received a petition requesting the use of march-in rights for Pfizer's Xalatan.
Schering-Plough’s Claritin settlement prompts letter from Grassley to Schering and 18 other manufacturers. Educating employees about the False Claims Act and their right to file suit is a “step in the right direction” to address fraud, he says.
Medco, Express Scripts and Cigna maintain that “automated” prior authorization is not feasible because it requires a discussion with the doctor. The PBMs recommend that HHS should support electronic transmission of prior authorization “where feasible.”